December 16, 2025 Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
October 2, 2025 Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
September 4, 2025 Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
August 21, 2025 Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
